• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Sagimet Biosciences Inc. - Series A Common Stock (NQ:SGMT)

    6.020 -0.190 (-3.06%)
    Streaming Delayed Price Updated: 10:55 AM EST, Jan 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Sagimet Biosciences Inc. - Series A Common Stock

    < Previous 1 2 3 4 Next >
    Get insights into the top gainers and losers of Thursday's after-hours session. ↗
    Via Chartmill
    News headline image
    Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study ↗
    Via Stocktwits
    News headline image
    Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
     
    Via Benzinga
    News headline image
    Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Positive Phase 3 Results for Denifanstat for the Treatment of Moderate to Severe Acne to be Presented at the EADV Congress 2025 by Partner Ascletis
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences Tops Q2 EPS Forecast ↗
    Via The Motley Fool
    News headline image
    Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗
     
    Via Benzinga
    News headline image
    Here are the top movers in Thursday's session. ↗
    Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session. 
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    News headline image
    These stocks are moving in today's pre-market session ↗
    Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
    Via Chartmill
    News headline image
    Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps ↗
    Denifanstat showed positive Phase 3 results in acne, meeting all goals with strong safety, as Sagimet pushes ahead with a second FASN inhibitor trial. 
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
     
    Via Benzinga
    News headline image
    Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
    From Sagimet Biosciences Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.